论文部分内容阅读
目的研究恩替卡韦与阿德福韦酯联合治疗既往抗病毒失败的慢性乙型病毒性肝炎的疗效与安全性。方法 34例既往抗病毒治疗失败的慢性乙型肝炎患者应用恩替卡韦联合阿德福韦酯治疗,以HBV DNA定量、肝功能、乙肝病毒定量作为观察指标,判断治疗后12、24、48、96周的疗效,疗程为96周。结果 34例患者丙氨酸氨基转移酶水平、HBV DNA载量、HBeAg滴度在治疗12、24、48、96周后均明显好转,疗程结束时19例患者完全应答,12例患者不完全应答,3例患者无应答,未发生严重不良反应。结论恩替卡韦联合阿德福韦酯在治疗既往抗病毒治疗失败的慢性乙肝患者中有良好疗效。
Objective To study the efficacy and safety of entecavir and adefovir dipivoxil in the treatment of chronic hepatitis B virus with previous antiviral failure. Methods Thirty-four patients with chronic hepatitis B who had failed previous antiviral therapy were treated with entecavir and adefovir dipivoxil. HBV DNA, liver function and hepatitis B virus (HBV) were quantitatively determined as the indicators of 12,24,48 and 96 weeks after treatment The curative effect is 96 weeks. Results The levels of alanine aminotransferase, HBV DNA load and HBeAg titers in all 34 patients were significantly improved after 12, 24, 48 and 96 weeks. At the end of the treatment period, 19 patients had complete response, 12 patients had incomplete response, 3 No patient response, no serious adverse reactions. Conclusion Entecavir combined with adefovir dipivoxil has good curative effect in the treatment of patients with chronic hepatitis B who have failed previous antiviral therapy.